Skip to main content

Table 6 Projected outcomes of six TB screening strategies for a cohort of 1000 healthcare workers: alternate scenario with confirmatory repeat interferon-gamma release assays (IGRAs) (use of two sequential positive IGRAs to identify candidates for treatment of LTBI)

From: Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis

Strategy

Cost in 2015 $CAN

QALYs

New active TB cases

Deaths due to active TB

Deaths due to adverse event to treatment of active TB

Deaths due to adverse event to treatment of LTBI

True positive results

False positive results

Post-exposure screening only

 Tuberculin SKIN Test

$66,387

15,239.98

3.03

0.13

0.0023

0.00036

63

6

 QuantiFERON®-TB-Gold

$77,521

15,239.85

2.97

0.13

0.0023

0.00040

67

11

Targeted screening

 Tuberculin Skin Test

$151,517

15,237.96

2.83

0.12

0.0022

0.00093

67

109

 QuantiFERON®-TB-Gold

$260,558

15,239.67

2.67

0.12

0.0020

0.00049

78

17

Annual screening

 Tuberculin Skin Test

$404,956

15,231.85

2.68

0.12

0.0020

0.00258

75

413

 QuantiFERON®-TB-Gold

$801,059

15,238.94

2.44

0.11

0.0019

0.00072

93

46

  1. TB tuberculosis, QALYS quality-adjusted life years, LTBI latent tuberculosis infection